More recently, Ian has been involved particularly in a number of.
Regulatory and patient safety risks are always high up the agenda for the pharmaceutical industry.The unfamiliar and the new are assessed as having higher risk than the known.. How manufacturing sits versus perceived value creation in the pharmaceutical companies.
In reality, pharmaceutical value creation comes from the development or acquisition of promising NCEs, and their ability to commercialise them.Manufacturing is complicated and costly and may be seen as a necessary inconvenience, rather than a potential strategic advantage..The locus of power and decision-making in companies.
Operational engineering and manufacturing drive the majority of investment plans and proposals.Their expertise, understanding and comfort lie with the plants and systems they work with every day.
This creates a natural inertia away from any transformation of technology or approach.. Capital governance processes skew decision-making and inhibit the new..
Significant investment approvals come to senior executives who rightly ask many difficult questions, while they may mistakenly expect and demand certainty.The simplicity of installation processes and manufacturing practices, like Poka-yoke, reduces reliance on skilled trades and enables accurate assembly using low-skilled operatives.
This opens up the workforce, allowing for greater diversity and inclusivity, and has been proven in various large-scale projects.. 4.Enhanced Productivity and Environmental Benefits:.
Research led by.Dr. Danny Murguia.